Form 4: Provectus Biopharmaceuticals Director Acquires 775,082 Stock Options

Director Webster Bailey acquired 775,082 stock options in Provectus Biopharmaceuticals on December 2, 2024.

Summary

• Webster Bailey, a director at Provectus Biopharmaceuticals, acquired 775,082 stock options on December 2, 2024.
• The stock options have an exercise price of $0.2862 per share.
• These options are exercisable starting December 2, 2024, and expire on December 2, 2034.
• The acquisition was a direct transaction.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a stock option grant to a director, which is neither particularly positive nor negative. It is a neutral event.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The terms of these options, such as the exercise price and expiration date, are typical for such grants.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, director, insider trading, beneficial ownership, Provectus Biopharmaceuticals, PVCT